ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Benefit and safety of capecitabine after resection of biliary tract cancer: a real-world study with propensity score matching
Provisionally accepted
Hugo Roussel*
Sophie Le Joncour
Valerie Aurillac
Arthur MarichezJean Frederic BlancLaurence Chiche
Christophe Laurent
Marie Decraecker*- Centre Hospitalier Universitaire de Bordeaux, Talence, France
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Biliary tract cancer (BTC) is a high mortality disease, with few patients eligible for resection. Even post-surgery, recurrence rates remain high. The benefit of capecitabine as adjuvant therapy is uncertain, as seen in the BILCAP trial results. This study aimed to evaluate the impact of capecitabine in a real-world setting among patients who underwent surgery for localized BTC. This retrospective observational study compared a cohort of patients who received adjuvant capecitabine with an observation-only cohort. Recurrence-free survival (RFS) and overall survival (OS) were estimated and compared between the two groups, with propensity score matching to minimize selection bias. Differences in RFS were also analyzed between patients completing the full capecitabine protocol and those on an adapted protocol. From January 2017 to May 2023, 117 patients were included in the observation cohort, and 43 patients were included in the capecitabine cohort. After propensity score matching, no difference in RFS was found (HR = 0.700, P = 0.34). Additionally, RFS was similar between patients who completed the full capecitabine protocol and those who received an adapted protocol (HR = 0.265, P = 0.19). This study showed no clear benefit of capecitabine; further research is needed to improve survival outcomes.
Keywords: adjuvant, Biliary Tract, capecitabine, Disease-Free Survival, Propensity Score
Received: 02 Sep 2025; Accepted: 14 Nov 2025.
Copyright: © 2025 Roussel, Le Joncour, Aurillac, Marichez, Blanc, Chiche, Laurent and Decraecker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hugo Roussel, hugo.roussel@chu-bordeaux.fr
Marie Decraecker, marie.decraecker@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.